BOSTON– Instem has announced the acquisition of Xybion Digital, a move that significantly expands its global presence and capabilities in the preclinical research and development (R&D) space. The deal includes the purchase of all outstanding shares of Xybion from Banerjee Group LLC, led by Dr. Pradip K. Banerjee.
Founded in 1977, Xybion is known for its flagship product, Pristima™, a cloud-based study management platform designed for GLP-compliant preclinical research. The company also offers solutions for laboratory information management (via the Autoscribe™ brand), R&D quality management (Xybion QMS™), and regulatory consulting services. Xybion serves clients in over 30 countries across five continents, including major pharmaceutical and contract research organizations.
Instem CEO Vik Krishnan called the acquisition a transformative milestone, saying it positions the newly combined entity as a global leader in preclinical life sciences software and services.
“The combination of these two companies effectively creates a ‘new Instem’—a leader with unparalleled scale and talent,” Krishnan said. “We will now have more resources to drive innovation and better serve our customers as they advance their research programs.”
Xybion was acquired in 2008 by Banerjee Group LLC, which expanded its offerings through acquisitions of Amadeus Solutions, Stelex, Vital Path from GE Healthcare, and Autoscribe Informatics.
By integrating Xybion’s platforms and experienced staff, Instem aims to offer a more comprehensive suite of solutions to address complex R&D challenges in regulated environments. The acquisition is expected to enhance Instem’s reach and impact in the pharmaceutical, biotech, and CRO sectors.
